-
Mashup Score: 2
In the STOPDAPT-3 trial, an aspirin-free strategy after PCI did not reduce major bleeding event risk compared with dual antiplatelet therapy, with data also suggesting a signal for excess coronary events, a speaker reported. DAPT with a P2Y12 inhibitor on top of aspirin therapy is the established treatment to prevent ischemic CV events, in particular stent thrombosis, at least 1 month after PCI;
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Antiplatelet therapy is a cornerstone of secondary prevention of cardiovascular diseases (CVDs). However, current guidelines are based on data derived primarily from men, as women are generally underrepresented in trials. Consequently, there are insufficient and inconsistent data on the effect of an …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
#SexDifferences in #antiplatelet therapy https://t.co/5mDQNGF5GT
-
-
Mashup Score: 0IL-6 receptor antagonists, antiplatelets show high probability of benefit for COVID-19 - 1 year(s) ago
IL-6 receptor antagonists and antiplatelet agents improved chances for 6-month survival among patients with COVID-19, according to study results presented at Society of Critical Care Medicine’s Critical Care Congress and published in JAMA.“In our analysis of longer-term outcomes among critically ill patients with COVID-19 who participated in the Randomized Embedded Multifactorial
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
“The beneficial effect of #antiplatelet agents in critically ill patients with #COVID-19 has not previously been demonstrated,” Lisa Higgins, PhD, MPH, lead of the health economics program at @anzicrc, told Healio. @iculisah https://t.co/DS9wCq8Mn5
-
-
Mashup Score: 1
Background: Evidence on the risk–benefit ratio of dual antiplatelet therapies among patients with stroke and impaired renal function is limited and inconsistent. Objective: To investigate the effect of renal function on the efficacy and safety of ticagrelor–aspirin versus clopidogrel–aspirin treatment. Design: Post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial….
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
An analysis of the CHANCE-2 trial has found that persons with normal #RenalFunction receive greater benefit from #antiplatelet therapy with ticagrelor #aspirin versus clopidogrel–aspirin: https://t.co/MII2Gxxx6z https://t.co/TILZ8WUk4G
-
-
Mashup Score: 2
Background: The efficacy and safety of prophylactic full-dose anticoagulation and antiplatelet therapy in critically-ill COVID-19 patients remains uncertain. Methods: COVID-PACT was a multicenter, 2×2 factorial, open-label, randomized-controlled trial with blinded endpoint adjudication …
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
#Anticoagulation and #Antiplatelet #Therapy for #Prevention of #Venous and #Arterial #Thrombotic #Events in #CriticallyIll Patients with #COVID-19: #COVID- #PACT https://t.co/PTs3oLoBwV https://t.co/TysIegiW5f
-
-
Mashup Score: 1Novel Factor XIa Inhibitors Show Promise for Bleeding Risk - 2 year(s) ago
Preventing ischemic events is a less clear benefit
Source: www.medpagetoday.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#ESCCongress: Researchers here showed overall enthusiasm for factor XIa inhibitors, which have been shown to keep #bleeding at bay when added to standard dual #antiplatelet therapy: https://t.co/gxH5V7cqHl @escardio @medpagetoday @HadleyWilsonMD
-
-
Mashup Score: 0
August 5, 2022 — For people with coronary heart disease, beta-blockers can improve survival and quality of life, while aspirin and other antiplatelet medications can reduce the risk of a heart attack. But those protections could backfire during hot-weather events, a time when heart attacks are more likely. A new study found that, among people suffering non-fatal heart attacks associated with hot…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @YaleMed For people with #coronary #heartdisease, beta-blockers can improve survival and quality of life, while #aspirin and other #antiplatelet medications can reduce the risk of a #heartattack: https://t.co/dIeLRZoM1b
-
-
Mashup Score: 1Optimal antiplatelet therapy in patients at high bleeding risk undergoing complex percutaneous coronary intervention - 2 year(s) ago
This editorial refers to ‘Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT tri
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Optimal antiplatelet therapy in patients at high bleeding risk undergoing complex PCI. Discover more in EHJ! https://t.co/7xvh1M0aGF #DAPT #antiplatelet #PCI #CAD #cardiotwitter @escardio @ESC_Journals
-
-
Mashup Score: 5Antiplatelet therapy after percutaneous coronary intervention - 2 year(s) ago
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: EuroInterventionCategories: Cardiology News and Journals, Latest HeadlinesTweet-
RT @ApoThera: #Antiplatelet therapy after percutaneous coronary intervention https://t.co/wz94UgqZYR #Cardiology #PCI #DOAC #Cathlab #Cardi…
-
-
Mashup Score: 0
AbstractAims. Gene expression biosignatures may hold promise to individualize antiplatelet therapy in conjunction with current guidelines and risk scores. The A
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A signature moment for #antiplatelet therapy✍️🏽 Using Aspirin Response Signature score to assess #risk of #bleeding in patients treated with #aspirin or #tricagrelor🩸 https://t.co/zNgsdhjMat @CVR_TomaszGuzik @DrMikeDrozd @glenpyle #ESCBasicScience #CardiovascularResearch https://t.co/fdi0Gu7rWM
-
The STOPDAPT-3 trial found that an #aspirin-free strategy following #PCI failed to reduce major #bleeding risk vs. dual #antiplatelet therapy. https://t.co/yaXZZAvQj5